Podcasts
REMS: Is it the end of the world as we know it? (part 1)
Date:
February 27, 2009
Speaker:
Peyton Howell
Description:
Risk Evaluation and Mitigation Strategies: For manufacturers, do REMS represent a tremendous potential for confusion or an opportunity for growth? Perhaps both. Manufacturers who implement effective programs can enhance patient access to medications, further ensure appropriate utilization and potentially improve patient outcomes. Manufacturers whose execution falls short stand to lose market share or even risk increased regulatory scrutiny.
Join us as we examine key operational and clinical considerations of successful REMS programs—what makes a program work and what impact it can have. Pharmaceutical Executive Editor Joanna Breitstein sits down with Peyton Howell, president of consulting services and health policy for AmerisourceBergen Specialty Group, to address these critical issues in the first of this two-part series.
Peyton Howell
President of consulting services and health policy
AmerisourceBergen Specialty Group
Interviewer : Joanna Breitstein
The Future of Oncology: How Public Policy, New Technology and Financial Considerations will Impact Cancer Care
With the U.S. healthcare system at an unprecedented crossroads, cancer care has emerged as one...
Date:
October 01, 2009
Speaker:
Mark Santos
The Changing Relationship between Pharma and Managed Care
Once viewed as the enemy, managed care has emerged as a necessary stakeholder and even...
Date:
July 07, 2009
Speaker:
Ken Trader
Driving Product Success through Patient Adherence and Compliance
Pharmaceutical manufacturers face unrelenting pressure to grow and protect market share for their products. At...
Date:
May 05, 2009
Speaker:
Jan Nielsen
REMS: Is it the end of the world as we know it? (part 2)
Risk Evaluation and Mitigation Strategies: For manufacturers, do REMS represent a tremendous potential for confusion...
Date:
March 25, 2009
Speaker:
Jay Jackson